Endocrine Abstracts

Introduction: Several clinical and molecular markers can be used to establish risk at the time of diagnosis in DTC. Thyroglobulin (Tg), which is essential in follow up, could be an early marker to identify risk patients. Around 25% of patients require 18 months or longer to have indetectable Tg. The presence of Tg antibodies (TgAb) invalidate the follow up of DTC via Tg and this is usually associated with a poor prognosis.Aim: To evaluate the role of Tg ...

Background and Objective: Semaglutide, a glucagon-like peptide 1 (GLP1a) receptor agonist, reduces the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus (DM2). An oral version of semaglutide is now available, and patients may prefer it to the subcutaneous form. Our objective was to compare the effectiveness and safety of both formulations in real life.Methods: Retrospective real-world efficacy analysis including aGLP1-...